Myovant Sciences initiated with a Buy at Goldman Sachs.
Goldman Sachs analyst Paul Choi started Myovant Sciences with a Buy rating and $20 price target. The "overreaction" on data concerns provides a good entry point into a stock with "attractive" pipeline optionality, Choi tells investors in a research note. The investor debate over the intermediate term will center on the market opportunity for the GnRH antagonist class and what share relugolix can attain, contends the analyst. Choi, however, thinks that the market has excessively discounted Myovant's prospects as his key opinion leader checks indicate no concerns about relugolix's placebo-adjusted response rate and enthusiasm for another treatment option for endometriosis and uterine fibroid.
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 28, 2019|
|Previous Article:||Melco announces deferral of acquisition of second tranche of shares in Crown.|
|Next Article:||MongoDB 'bull case' price target raised to $284 from $185 at Morgan Stanley.|